Integrative Genetics Analysis of Juvenile Idiopathic Arthritis Identifies Novel Loci
Yun R. Li,Jin Li,Joseph T. Glessner,Jie Yang,Michael E. March,Charlly Kao,Jonathan P. Bradfield,Junyi Li,Frank D. Mentch,Huiqi Qu,Xiaohui Qi,Xiao Chang,Cuiping Hou,Debra J. Abrams,Haijun Qiu,Zhi Wei,John J. Connolly,Fengxiang Wang,James Snyder,Sophie Limou,Berit Flatø,Øystein Førr,Susan D. Thompson,Carl D Langefeld,David N Glass,Mara L. Becker,Elena Perez,Benedicte A. Lie,Marilynn Punaro,Debra K Shivers,Justine A. Ellis,Jane E. Munro,Carol Wise,Patrick M.A. Sleiman,Hakon Hakonarson
DOI: https://doi.org/10.1101/2020.09.01.20185603
2020-01-01
Abstract:Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis among children, encompassing a highly heterogeneous group of immune-mediated joint disorders, being classified into seven subtypes based on clinical presentation.
To systematically understand the distinct and shared genetic underpinnings of JIA subtypes, we conducted a heterogeneity-sensitive GWAS encompassing a total of 1245 JIA cases classified into 7 subtypes and 9250 controls. In addition to the MHC locus, we uncovered 16 genome-wide significant loci, among which 15 were shared between at least two JIA subtypes, including 11 novel loci. Functional annotation indicates that candidate genes at these loci are expressed in diverse immune cell types. Further, based on the association results, the 7 JIA subtypes were classified into two groups, reflecting their autoimmune vs autoinflammatory nature.
Our results suggest a common genetic mechanism underlying these subtypes in spite of their different clinical disease phenotypes, and that there may be drug repositioning opportunities for rare JIA subtypes.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
The study was supported by Institutional Development Funds from the Children's Hospital of Philadelphia to the Center for Applied Genomics, The Children's Hospital of Philadelphia Endowed Chair in Genomic Research to HH, and the grant U01-HG006830 (NHGRI-sponsored eMERGE Network) to HH.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Boards of CHOP and other collaborating centers approved this study, and written informed consent was obtained from all subjects (or their legal guardians).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
To have access to the data reported in this manuscript, please contact the corresponding author Dr. Hakon Hakonarson.